#vaginal microbicide

An analysis of a previous study of a tenofovir-based vaginal gel found that women with vaginal inflammation were less protected.

A one-month version of the ring is currently up for regulatory approval.

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

A vaginal microbicide against HIV worked much less well among those with a certain dominant type of bacteria.

A trial of a Viread (tenofovir)-containing vaginal gel to protect against HIV has failed because the South African women participants used it...

The failure of the VOICE trial of oral and vaginal gel PrEP was the result of low adherence among the sub-Saharan African women participants,...

Many young women dream about walking down the aisle at their wedding—they imagine the floral arrangements, the dress, the venue.

A vaginal gel with the HIV drug tenofovir, which was created to reduce the odds of HIV transmission, has proved surprisingly effective against...

Years ago, when I went to my first HIV doctor’s appointment, he reviewed a list of specific sexual activities in an effort to ascertain...

The Follow-on African Consortium for Tenofovir Studies (FACTS)-a vaginal microbicide follow-up to the CAPRISA 004 study-is expected to begin l...

A study funded by the National Institutes of Health (NIH) has confirmed that treating HIV-positive people with antiretroviral (ARV) drugs...

A vaginal gel may also work as a form of HIV prevention for anal sex.

U.S. women involved in a study comparing the safety, blood levels and acceptability of two methods of pre-exposure prophylaxis (PrEP) to preve...

Oral pre-exposure prophylaxis (PrEP) may be the next focus of HIV prevention efforts, The New York Times report.

A promising HIV-fighting vaginal gel may be shelved due to lack of funding, The New York Times reports.